Blood test markers in newly diagnosed ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at two simple blood tests in people newly diagnosed with ALL (a type of blood cancer) to see if these tests can help predict how the disease might progress. It may help doctors understand your condition better and could lead to more personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with ALL (acute lymphoblastic leukemia) and have not started any treatment yet.
- You cannot have any other blood disorders besides ALL.
- You cannot have had another cancer before, or have ALL that has come back.
- You cannot be currently receiving chemotherapy or radiation therapy.
- You cannot have signs of infection or inflammation (like fever or swelling).
- You cannot have an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the gut microbiome (tiny organisms in the gut) and metabolome (small chemicals in the body) in children and teens with newly diagnosed ALL. It may help researchers understand what is happening in the body early in treatment and could guide future, more personalized care.
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
This study looks at routine blood test results (called CBC) in people who have just been diagnosed with acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if certain blood levels can help doctors understand the disease better and guide treatment.
This study looks at whether a simple blood test can help predict outcomes in patients with newly diagnosed acute leukemia. The test measures the ratio of two proteins in your blood, which might give doctors clues about how the disease will progress.
This study checks if two natural substances in your blood (called cytokines) are linked to how active your leukemia is. It aims to help doctors better understand and possibly predict the disease, which could guide future treatment.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.